18 F-NaF, a PET radiotracer of bone turnover, has shown potential as an imaging biomarker for assessing the response of bone metastases to therapy. This study aimed to evaluate the repeatability of 18 F-NaF PET-derived SUV imaging metrics in individual bone lesions from patients in a multicenter study. Methods: Thirty-five castration-resistant prostate cancer patients with multiple metastases underwent 2 whole-body (test-retest) 18 F-NaF PET/CT scans 3 ± 2 d apart from 1 of 3 imaging sites. A total of 411 bone lesions larger than 1.5 cm 3 were automatically segmented using an SUV threshold of 15 g/mL. Two levels of analysis were performed: lesion-level, in which measures were extracted from individual-lesion regions of interest (ROI), and patient-level, in which all lesions within a patient were grouped into a patient ROI for analysis. Uptake was quantified with SUV max , SUV mean , and SUV total . Test-retest repeatability was assessed using BlandAltman analysis, intraclass correlation coefficient (ICC), coefficient of variation, critical percentage difference, and repeatability coefficient. The 95% limit of agreement (LOA) of the ratio between test and retest measurements was calculated. Results: At the lesion level, the coefficient of variation for SUV max , SUV mean , and SUV total was 14.1%, 6.6%, and 25.5%, respectively. At the patient level, it was slightly smaller: 12.0%, 5.3%, and 18.5%, respectively. ICC was excellent (.0.95) for all SUV metrics. Lesion-level 95% LOA for SUV max, SUV mean , and SUV total was (0.76, 1.32), (0.88, 1.14), and (0.63, 1.71), respectively. Patient-level 95% LOA was slightly narrower, at (0.79, 1.26), (0.89, 1.10), and (0.70, 1.44), respectively. We observed significant differences in the variance and sample mean of lesion-level and patient-level measurements between imaging sites. Conclusion: The repeatability of SUV max , SUV mean , and SUV total for 18 F-NaF PET/CT was similar between lesion-and patient-level ROIs. We found significant differences in lesion-level and patient-level distributions between sites. These results can be used to establish 18 F-NaF PET-based criteria for assessing treatment response at the lesion and patient levels. 18 F-NaF PET demonstrates repeatability levels useful for clinically quantifying the response of bone lesions to therapy.

Purpose [F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastases. This study assesses changes in early NaF PET/CT response measures in metastatic prostate cancer for correlation to clinical outcomes. Patients and Methods Fifty-six patients with metastatic castration-resistant prostate cancer (mCRPC) with osseous metastases had NaF PET/CT scans performed at baseline and after three cycles of chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 40). A novel technology, Quantitative Total Bone Imaging, was used for analysis. Global imaging metrics, including maximum standardized uptake value (SUV) and total functional burden (SUV), were extracted from composite lesion-level statistics for each patient and tracked throughout treatment. Progression-free survival (PFS) was calculated as a composite end point of progressive events using conventional imaging and/or physician discretion of clinical benefit; NaF imaging was not used for clinical evaluation. Cox proportional hazards regression analyses were conducted between imaging metrics and PFS. Results Functional burden (SUV) assessed midtreatment was the strongest univariable PFS predictor (hazard ratio, 1.97; 95% CI, 1.44 to 2.71; P < .001). Classification of patients based on changes in functional burden showed stronger correlation to PFS than did the change in number of lesions. Various global imaging metrics outperformed baseline clinical markers in predicting outcome, including SUV and SUV. No differences in imaging response or PFS correlates were found for different treatment cohorts. Conclusion Quantitative total bone imaging enables comprehensive disease quantification on NaF PET/CT imaging, showing strong correlation to clinical outcomes. Total functional burden assessed after three cycles of hormonal therapy or chemotherapy was predictive of PFS for men with mCRPC. This supports ongoing development of NaF PET/CT-based imaging biomarkers in mCRPC to bone.

Identification of individual lesions on 18 F-NaF PET bone scans is a time-consuming and often subjective process that makes accurate characterization of disease burden challenging. Current automated methods either underestimate disease or struggle with high false positive rates. We developed a statistically optimized regional thresholding (SORT) method that optimizes detection of bone lesions.This study assessed 18 F-NaF PET/CT scans of 37 bone metastatic prostate cancer patients. Each PET image was divided into 19 skeletal regions. Areas of disease in each skeletal region were identified by an experienced nuclear medicine physician. A region of interest (ROI) was placed at each disease location and local maxima were extracted for both healthy and diseased ROIs. Secondary physician review was performed after identification of suspicious local maxima. Region-specific SUV thresholds were determined based on receiver operating characteristic (ROC) analysis optimized for detection of malignant disease. The detection performance of the SORT thresholds were compared to commonly used SUV > 10 g ml −1 (SUV 10 ) and SUV > 15 g ml −1 (SUV 15 ) global thresholds. The sensitivity of the SORT thresholds to various factors was evaluated, such as the number of subjects evaluated or image reconstruction settings.1751 lesions were manually identified by the nuclear medicine physician. SORT identified different thresholds in each skeletal region (SUV range: 3-13 g ml −1 ). Region-specific SORT thresholding resulted in higher sensitivity (95.8%) than commonly used global thresholds (82.8% for SUV 10 and 58.4% for SUV 15 ) while maintaining a high specificity (97.1%, compared to 97.3% for SUV 10 and 100.0% for SUV 15 ). Factors, such as reconstruction settings, had minimal impact on threshold optimization, resulting in an average change of 10% (range: 2%-17%) in thresholds for each factor.Region-specific SUV thresholding of NaF PET images for bone lesion detection in metastatic prostate patients was found to be superior to current global thresholding methods.

No abstract

No abstract

Purpose: Clinical use of 18F‐Sodium Fluoride (NaF) PET/CT in metastatic settings often lacks technology to quantitatively measure full disease dynamics due to high tumor burden. This study assesses radiomics‐based extraction of NaF PET/CT measures, including global metrics of overall burden and local metrics of disease heterogeneity, in metastatic prostate cancer for correlation to clinical outcomes. Methods: Fifty‐six metastatic Castrate‐Resistant Prostate Cancer (mCRPC) patients had NaF PET/CT scans performed at baseline and three cycles into chemotherapy (N=16) or androgen‐receptor (AR) inhibitors (N=39). A novel technology, Quantitative Total Bone Imaging (QTBI), was used for analysis. Employing hybrid PET/CT segmentation and articulated skeletal‐registration, QTBI allows for response assessment of individual lesions. Various SUV metrics were extracted from each lesion (iSUV). Global metrics were extracted from composite lesion‐level statistics for each patient (pSUV). Proportion of detected lesions and those with significant response (%‐increase or %‐decrease) was calculated for each patient based on test‐retest limits for iSUV metrics. Cox proportional hazard regression analyses were conducted between imaging metrics and progression‐free survival (PFS). Results: Functional burden (pSUVtotal) assessed mid‐treatment was the strongest univariate predictor of PFS (HR=2.03; p<0.0001). Various global metrics outperformed baseline clinical markers, including fraction of skeletal burden, mean uptake (pSUVmean), and heterogeneity of average lesion uptake (pSUVhetero). Of 43 patients with paired baseline/mid‐treatment imaging, 40 showed heterogeneity in lesion‐level response, containing populations of lesions with both increasing/decreasing metrics. Proportion of lesions with significantly increasing iSUVmean was highly predictive of clinical PFS (HR=2.0; p=0.0002). Patients exhibiting higher proportion of lesions with decreasing iSUVtotal saw prolonged radiographic PFS (HR=0.51; p=0.02). Conclusion: Technology presented here provides comprehensive disease quantification on NaF PET/CT imaging, showing strong correlation to clinical outcomes. Total functional burden as well as proportions of similarly responding lesions was predictive of PFS. This supports ongoing development of NaF PET/CT based imaging biomarkers in mCRPC. Prostate Cancer Foundation

Translation of wound healing research is limited by the lack of an appropriate animal model, due to the anatomic and wound healing differences in animals and humans. Here, we characterize healing of grafted, full‐thickness human skin in an in vivo model of wound healing. Full‐thickness human skin, obtained from reconstructive operations, was grafted onto the dorsal flank of NOD.Cg‐KitW41J Tyr + Prkdcscid Il2rgtm1Wjl/ThomJ mice. The xenografts were harvested 1 to 12 weeks after grafting, and histologic analyses were completed for viability, neovascularization, and hypoxia. Visual inspection of the xenograft shows drying and sloughing of the epidermis starting at week four. By week 12, the xenograft appears healed but has lost 63.05 ± 0.24% of the initial graft size. There is histologic evidence of epidermolysis as early as 2 weeks, which progresses until week 4, when new epidermis appears from the wound edges. Epidermal regeneration is complete by week 12, although the epidermis appears hypertrophied. An initial increase of infiltrating immune mouse cells into the xenograft normalizes to baseline 6 months after grafting. Neovascularization, as evidenced by positive staining for the proteins human CD31 and alpha smooth muscle actin, is present as early as 2 weeks after grafting at the interface between the xenograft and the mouse tissue. CD31 and alpha smooth muscle actin staining increased throughout the xenograft over the 12 weeks, leading to greater viability of the tissue. Likewise, there is increased Hypoxia Inducible Factor 1‐alpha expression at the interface of viable and nonviable tissue, which suggest a hypoxia‐driven process causing early graft loss. These findings illustrate human skin wound healing in an ischemic environment, providing a timeline for use of full thickness human skin after grafting in a murine model to study mechanisms underlying human skin wound healing.

Background The skills required for supermicrosurgery are hard-earned and difficult to master. The University of Wisconsin “blue-blood” chicken thigh model incorporates perfusion of the thigh vessels with a blue liquid solution, allowing users to visualize flow across their anastomoses. This model has proven to be an excellent source of small vessels (down to 0.3 mm) but assessing the quality of anastomoses at this spatial scale has proven difficult. We evaluated whether fluorescent imaging with indocyanine green (ICG) in this realistic training model would enhance the assessment of supermicrosurgical anastomoses, and therefore improve real-time feedback to trainees. Methods Anastomoses of vessels ranging from 0.35 to 0.55mm in diameter were performed followed by the capture of white light with and without fluorescence imaging overlay during infusion of “blue-blood” and ICG. Videos were randomized and shown to seven fellowship-trained microsurgeons at the University of Wisconsin-Madison who rated each anastomosis as “patent,” “not patent,” or “unsure.” Surgeon accuracy, uncertainty, and inter-rater agreement were measured for each imaging modality. Results Use of fluorescence significantly increased surgeon accuracy to 91% compared with 47% with white light alone (p = 0.015), decreased surgeon uncertainty to 4% compared with 41% with white light alone (p = 0.011), and improved inter-rater agreement from 53.1% with white light alone to 91.8% (p = 0.016). Conclusion Augmentation of the University of Wisconsin “blue-blood” chicken thigh model with ICG fluorescence improves accuracy, decreases uncertainty, and improves inter-rater agreement when assessing supermicrosurgical anastomoses in a training setting. This improved, real-time feedback enhances this model's value as a supermicrosurgical training tool.